David F. Claxton, M.D.

Hematology/Oncology

Leukemia and Bone Marrow Disorders Stem Cell Transplantation Hematologic Malignancies Tumor Immunotherapy Mini Allogeneic Transplant

Dr. Claxton received his MD from McGill University in Montreal Canada in 1978 and completed an Internal Medicine Residency in 1983. He then pursued a Hematology Fellowship followed by an Oncology Fellowship, which he completed at the M.D. Anderson Cancer Center in 1990. He was subsequently a faculty member at M.D. Anderson in the Department of Blood and Marrow Transplantation until he left M.D. Anderson in year 2000 to come to Penn State Hershey Cancer Institute. At Penn State, he was promoted to full Professor. His responsibilities at Penn State have included patient care in the areas of hematological malignancies and leukemia treatments, blood and marrow transplantation, teaching, research, and administration.

Currently, Dr. Claxton is actively involved in patient care of patients with blood malignancies. His clinical focus is on leukemia s and myelodysplastic syndrome and bone marrow transplantation. He teaches medical students, residents, and sub-specialty fellows. He has numerous publications in the field of leukemia molecular biology and therapeutics. He has active clinical research interests in leukemia therapeutics and is also active in translational and bench research and leukemia therapeutics.

Fellowship, Oncology, M.D. Anderson Cancer Center (1990) Fellowship, Hematology, Royal Victoria Hospital (1986) Residency, Internal Medicine, Royal Victoria Hospital (1984) Internship, Rotating, Royal Jubilee Hospital (1979) M.D., McGill University, Faculty of Medicine (1978)

Leukemia treatment - in particular, acute myelogenous leukemia

Immunotherapy of leukemia

Blood and marrow transplantation for hematological malignancies

Clinical trials and leukemia, myelodysplastic syndrome, lymphoma, bone marrow transplantation

Dr. Claxton regularly lectures to medical students, residents, and subspecialty fellows.

Claxton DF, Liu P, Hsu HB, Marlton P, Hester J, Collins F, Deisseroth AB, Rowley JD, Siciliano MJ
Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia
Blood 83(7): 1750-1756, 1994 Choudhury A, Liang JC, Thomas EK, Flores-Romo L, Xie QS, Agusala K, Sutaria S, Sinha I, Champlin RE, Claxton DF
Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, anti-leukemic responses
Blood 93: 780-786, 1999 Claxton DF, Ehmann WC, Rybka W
Control of advanced and refractory acute myelogenous leukemia with sirolimus based non-myeloablative allogeneic stem cell transplantation Jul 2005
British Journal of Haematology 130(2): 256-26 von Reyn Cream L, Ehmann WC, Rybka W, Claxton DF
Sirolimus in unmanipulated haploidentical cell transplantation
Bone Marrow Transplantation 42: 765-6, 2008 Kantarjian HM, Erba HP, Claxton DF, Arellano M, Lyons RM, Kovascovics T, Gabrilove J, Craig M, Douer D, Maris M, Petersdorf S, Shami PJ, Yeager AM, Eckert S, Abichandani R, Faderl S
Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults with Acute Myeloid Leukemia and Unfavorable Prognostic Factors Dec 2009
Journal of Clinical Oncology